Novo Nordisk 2021Q3 – Wegovy┬« bottlenecks

Novo Nordisk continues to succeed in the GLP-1 space with semaglutide (Ozempic┬«, Rybelsus┬« and Wegovy┬«). Highlights of the quarter include initiation of phase 3a trials with oral semaglutide in obesity and ziltivekimab in cardiovascular disease. Novo Nordisk now has late stage clinical trials in all of their therapy areas. Ozempic┬« continues to be one of …